Merck (MRK) Liabilities from Discontinued Operations (2014 - 2020)
Merck's (MRK) quarterly Liabilities from Discontinued Operations came in at $1.1 billion in Q4 2020, up 34.07% quarter-over-quarter from $810.0 million in Q3 2014.
Powered by 
Analysis
Merck (MRK) Liabilities from Discontinued Operations (2014 - 2020) Analysis & Trends
Merck (MRK) has reported Liabilities from Discontinued Operations for 2 consecutive years, with $1.1 billion the latest figure, recorded in Q4 2020.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to $1.1 billion in Q4 2020; TTM through Dec 2020 was $1.1 billion, a N/A change from a year earlier, with the FY2020 full-year figure at $1.1 billion, changed N/A from the prior year.
- Liabilities from Discontinued Operations was $1.1 billion for Q4 2020 at Merck, up from $810.0 million in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at $1.1 billion in Q4 2020 and troughed at $1.1 billion in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 1.09 Bn |
| Sep 30, 2014 | 810.00 Mn |
| Jun 30, 2014 | 801.00 Mn |
| Mar 31, 2014 | 848.00 Mn |